What is AVITA Medical, Inc.'s current stock price?

AVITA Medical, Inc. (RCEL) currently trades at USD 3.71. Track real-time price changes and historical performance on AllInvestView.

What sector is AVITA Medical, Inc. in?

AVITA Medical, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

AVITA Medical, Inc.

🧾 Earnings Recap – Q3 2025

AVITA Medical reported Q3 2025 revenues of approximately $17 million, falling short of expectations due to ongoing reimbursement disruptions, but anticipates renewed demand and adoption for its RECELL product following resolution of payment clarity.

Revenue guidance for the full year adjusted to $70 million to $74 million, down from $76 million to $81 million.
All seven regional Medicare Administrative Contractors have established reimbursement rates for RECELL, enhancing clinician confidence and adoption.
The company is refining its commercial strategies, focusing on approximately 200 key burn centers, representing a $1.3 billion opportunity within the broader $3.5 billion U.S. market.
Recent CE Mark approval for RECELL GO expands access to the technology in Europe, with the first patient treated in Germany.
Management's immediate priorities include revitalizing order momentum, driving consistent product utilization, and finalizing the transition of the commercial organization for improved performance.

View full recap page

AVITA Medical, Inc. Analysis (RCEL)

United States Health Care Official Website Stock

Is AVITA Medical, Inc. a good investment? AVITA Medical, Inc. (RCEL) is currently trading at 3.71 USD. Market analysts have a consensus price target of 8.31 USD. This suggests a potential upside from current levels.

Earnings Schedule: AVITA Medical, Inc. is expected to release its next earnings report on May 6, 2026. The market consensus estimate for Forward EPS is -0.20.

Investor FAQ

Does AVITA Medical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AVITA Medical, Inc.?

AVITA Medical, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 6, 2026. The company currently has a trailing EPS of -1.74.

Company Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Split Date	Split Ratio to 1
June 30, 2020	0.200000

Split Date

Split Ratio to 1

June 30, 2020

0.200000

AVITA Medical, Inc. RCEL Open AVITA Medical, Inc. in new tab

AVITA Medical, Inc.

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features